Enacitib 50 mg / 100 mg (Enasidenib)

Enacitib (Enasidenib), generic Idhifa is a prescription medicine used to treat patients with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatments. Discover Enacitib 50 mg (Enasidenib) by Everest Pharmaceutical Ltd., a breakthrough in targeted therapy for relapsed or refractory AML with IDH2 mutations.

Enacitib 50 mg (Enasidenib) Tablets by Ziska Pharmaceuticals Limited, supplied by Onco Solution. Effective treatment for acute myeloid leukemia (AML). Enacitib Enasidenib is a potent inhibitor of mutant isocitrate dehydrogenase 2 (IDH2), an enzyme frequently mutated in acute myeloid leukemia (AML).

Enacitib (Enasidenib), generic Idhifa is a prescription medicine used to treat patients with acute myeloid leukemia (AML) with an isocitrate dehydrogenase. Enacitib (Enasidenib), generic Idhifa is a prescription medicine used to treat patients with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2. IDHIFA is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. Ziska Oncology & Biotech with the most advanced targeted therapies, biotech products, monoclonal antibodies & immunotherapies to treat patients more precisely.